Nicotinic Receptors and Schizophrenia

Nicotinic Receptors and Schizophrenia

The study determines if a new preparation of a drug designed to treat schizophrenia is more slowly released into the body.

3-2,4 dimethoxybenzylidene will be compounded with a methyallose compound in doses of 150 and 300 mg. The capsules will be administered singly and eventually bid to determine if sustained blood levels comparable to steady state blood levels seen in previous studies can be determined. Safety and EEG effects will be measured.

Inclusion Criteria:

• Healthy volunteers: males and females who are incapable of pregnancy

Exclusion Criteria:

• Medical illnesses requiring acute treatment
• History of seizures
• Substance abuse including nicotine